Separate terms with OR to return results that match either term.
Clear All

669 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year (Descending) FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
NA Selumetinib Koselugo 10mg, 25mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2020 In Use
NA Tazemetostat Tazverik 200mg Chemotherapy Enzyme Inhibitor EZH2 Yes 2020 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
J9318 Romidepsin, non-lyophilized Romidepsin 0.1mg Chemotherapy Enzyme Inhibitor HDAC No 2020 Sept. 27, 2021 In Use
Q5116 Trastuzumab-qyyp Trazimera 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Oct. 1, 2019 In Use
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan. 1, 2019 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 July 1, 2019 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct. 1, 2019 In Use
Q5118 Bevacizumab-bvcr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct. 1, 2019 In Use

Found 669 results in 1 millisecondExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.